key: cord-1016010-a1b3ztu7 authors: Sun, K.; Tempia, S.; Kleynhans, J.; Gottberg, A. v.; McMorrow, M. L.; Wolter, N.; Bhiman, J. N.; Moyes, J.; Plessis, M. d.; Carrim, M.; Buys, A.; Martinson, N. A.; Kahn, K.; Tollman, S.; Lebina, L.; Wafawanaka, F.; Toit, J. d.; Gomez-Olive, F. X.; Mkhencele, T.; Viboud, C.; Cohen, C. title: Persistence of SARS-CoV-2 immunity, Omicron's footprints, and projections of epidemic resurgences in South African population cohorts. date: 2022-02-13 journal: nan DOI: 10.1101/2022.02.11.22270854 sha: 8f7637817bd4730a3c9f203a46c046e72389ccef doc_id: 1016010 cord_uid: a1b3ztu7 Understanding the build-up of immunity with successive SARS-CoV-2 variants and the epidemiological conditions that favor rapidly expanding epidemics will facilitate future pandemic control. High-resolution infection and serology data from longitudinal household cohorts in South Africa reveal high cumulative infection rates and durable cross-protective immunity conferred by prior infection in the pre-Omicron era. Building on the cohort's history of past exposures to different SARS-CoV-2 variants and vaccination, we use mathematical models to explore the fitness advantage of the Omicron variant and its epidemic trajectory. Modelling suggests the Omicron wave infected a large fraction of the population, leaving a complex landscape of population immunity primed and boosted with antigenically distinct variants. Future SARS-CoV-2 resurgences are likely under a range of scenarios of viral characteristics, population contacts, and residual cross-protection. with Omicron replacing Delta in multiple global locations, even when prevalence of Delta was high (9, 10). The apparent fitness advantage of the Omicron variant over Delta could be driven by immune evasion, increased intrinsic transmissibility, or a combination of both. The immune evasion hypothesis is supported by an increased reinfection risk coinciding with the rise of the Omicron 5 variant (7, 8, 11, 12) . Further support for this hypothesis comes from in vitro analyses of sera from convalescent patients (infected with pre-Omicron variants) and vaccinated individuals, which show reduced neutralization titers against Omicron compared to earlier variants (13) (14) (15) (16) . Similarly, data from multiple settings have shown decreased vaccine effectiveness against Omicron (17, 18) . Separately, epidemiological and experimental data point to a reduced clinical 10 severity of Omicron (17, 19) , possibly due to increased tropism for the upper respiratory tract rather than the lung, which could also promote higher transmission relative to pre-Omicron variants. As the Omicron wave subsides, the relative contribution of these factors to Omicron's spread remains elusive, in part due to uncertainty in the level of population immunity before the rise of Omicron. Further, Omicron's rapid spread poses immense pressure on SARS-CoV-2 testing 15 capabilities, and its relatively benign course in most people make it difficult to assess the full scope of the epidemic. To understand the long-term dynamics of SARS-CoV-2, we leveraged data from two longitudinal household cohorts followed over a 13-month period, from July 2020 to August 2021 in rural and urban areas of South Africa (Prospective Household study of SARS-CoV-2, Influenza episode. The cumulative infection rate (confirmed by either a rRT-PCR or a serological test) was 69.4% (387/557) in the urban cohort by the end of the study. In total across both sites, we observed 669 rRT-PCR-confirmed infection episodes, including 599/669 (89.5%) primary infections and 70/669 (9.5%) reinfections. Lineage-specific rRT-PCR and sequencing data revealed that 14.3% (96/669) of infections were D614G, 33.2% (222/669) 5 were Beta, 44.1% (295/669) were Delta, 2.7% were other lineages, and 5.7% (38/669) were inconclusive. Figure 1 E-F shows the relative prevalence of different lineages over time for the rural and urban site, respectively (details in Materials and Methods Section 3.2). To study the risk of infection and re-infection in the cohort, and better understand acquisition 10 of immunity before the rise of Omicron, we first built a time-varying model that captured the dynamics of viral RNA shedding for each individual in the cohort, adjusted for host characteristics and variant types. Household exposure depends on the level of viral shedding among household members; to obtain a correlate of shedding intensity, we used the serial Ct values of nasal swab specimens collected twice-weekly and tested for SARS-CoV-2 using rRT-PCR. We considered 15 the difference between the Ct value of the rRT-PCR test of a specimen and the Ct value of the detection limit of our rRT-PCR assay as a proxy for the RNA shedding intensity (refer to as dCt hereafter). We used the serial rRT-PCR test results to model the shedding kinetics of SARS-CoV-2 infection episodes, as have others (22, 23) . To account for the potential role of adaptive immunity in limiting transmission in the later phases of infection, we allowed for different transmission risks 20 during the viral RNA proliferation stage (before peak shedding) and the viral RNA clearance stage (after peak shedding), with shedding increases and decreases assumed to following linear curves on the scale of Ct values. Because the nasal swab sampling period ended on August 28, 2021, around the peak of the Delta wave in both sites, we limit our analysis to infection episodes with first positive PCR specimen 30 days prior to the end of sampling to avoid censoring bias. (1.6 -3.4) days, Delta: 3.0 (1.9 -3.7) days) and a longer clearance stage ( Figure 2F , median and . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 13, 2022. ; https://doi.org /10.1101 /10. /2022 IQR for D614G: 7.1 (3.0 -10.9) days, 3) days, Delta: 7.9 (3.9 -10.8) days). After adjusting for age, sex, body mass index (BMI), and HIV infection status, symptomatic infections had significantly higher peak dCt value (peak shedding intensity) than asymptomatic infections ( Figure 2H ). Beta variant's peak dCt value was higher than D614G, while Delta's was the highest among the three ( Figure 2H ). In addition, individuals infected with the Delta variant 5 shed RNA for significantly longer than D614G ( Figure 2I ). We found that prior infection significantly reduced peak shedding by 3.7 Ct (95% CI 2.0 -5.5) and shedding duration by 3.6 days (95% CI 2.0 -5.2) upon reinfection ( Figure 2H -I). The population of the PHIRST-C cohort had a high prevalence of HIV, 13% in the rural site and 16% in the urban site, reflecting the burden of HIV infections in South Africa. However, in this 10 cohort, most (93.8%) persons living with HIV (PLWH) had CD4+ T cell counts ≥ 200 cells/ml, and they did not differ from HIV-uninfected individuals in terms of SARS-CoV-2 shedding ( Figure 2H -I). We found that individuals with low CD4+ T cell counts (< 200 cells/ml) tended to shed for longer and with higher peak dCt when compared to HIV-uninfected individuals but there was limited statistical power to detect these differences ( Figure 2H -I). 15 Reconstruction of the variant-specific shedding kinetics of each infected individual allowed us not only to infer the timing of their infections, but also to evaluate the daily intensity of exposure to SARS-CoV-2 within their households. We used logistic regression to explore how variant type and prior infection history affect the risk of SARS-CoV-2 infection and reinfection, after 8 level SARS-CoV-2 surveillance information to reconstruct SARS-CoV-2's antigen exposure (s) history in this population, considering infections and/or vaccinations through time ( Figure 3F ). We then built a variant-specific transmission model to capture the declining phase of the Delta wave after the end of the PHIRST-C study and infer the population-level transmission rate during that time. Next, we added a second strain to our model to account for Omicron's dynamics, with free 5 parameters representing the relative infectiousness of Omicron vs Delta ! "#$%&'( / ! )*+,-, Omicron's degree of immune evasion against infection among individuals infected by prior variants "# $ , and Omicron's degree of immune evasion against transmission given reinfection "# ,|$ (with higher values of "# $ $ "# ,|$ % indicating higher degrees of immune evasion, where "# $ $ "# ,|$ % = 0 corresponds to no evasion while "# $ $ "# ,|$ % = 1 indicates 100% evasion, detailed 10 in Materials and Methods Section 4). We explored the parameter space and initial conditions of Omicron's introduction and selected epidemic trajectories that were compatible with the observed growth advantage of Omicron over Delta and the peak timing of the Omicron wave -the two most reliable epidemiologic observations during the Omicron epidemic. We then evaluated Omicron's possible epidemic trajectories for the remaining parameters conditional on the observed growth 15 rate and peak timing. Lastly, we selected one scenario that was most compatible with independent evidence on the degree of Omicron's immune evasion and projected the likelihood of resurgence of different variants ( Figure 3F ). Assuming that the Delta variant was in an exponentially declining phase after week 35 of 2021 and that the Omicron variant was growing exponentially until week 48 of 2021 in the study urban 20 district (20), we estimated that the daily growth rate was -0.063 for Delta and 0.275 for Omicron, which translates into a growth advantage of 0.338 per day for Omicron over Delta ( Figure S3 ). The transmission models of Delta and Omicron were calibrated to match their observed growth rates during this period, respectively. In Figure 3A , we show the trade-off between the estimated ratio of basic reproduction numbers between Omicron and Delta ! "#$%&'( / ! )*+,and different number for the Omicron variant to match the observed epidemic trajectory. We also found that for all parameters explored, the Omicron epidemic led to higher infection rates than prior epidemic waves, with the most optimistic scenario resulting in an infection rate above 40%. Higher degrees of immune evasion resulted in higher infection rates ( Figure 3B ). Infections were expected to accumulate within a relatively short period of time, with epidemic duration (measured as 4 times 5 the standard deviation of the onset dates of all infections within the epidemic wave) projected to range from 31 -37 days depending on the parameters. Notably, our model projected that a large fraction of Omicron infections (>40%) would be reinfections or vaccine breakthrough infections, with higher proportions observed for higher immune evasion parameters ( Figure 3D ). Furthermore, a low rate of clinical cases was projected for Omicron, after controlling for the 10 number of infections due to this variant. The projected infection case ratio (ICR) for Omicron ranged from 0.4% to 0.9% ( Figure 3E ), much lower than the ICRs of 3.6%, 3.3%, and 9.4% estimated for the D614G, Beta, and Delta waves (Table S1 ). In sensitivity analyses ( Figure S5 ), we further explored the impact of Omicron mean generation times ranging from 3-6 days (22). To estimate the immune footprint of the Omicron wave and project a post-Omicron future, we 15 considered a reference scenario for Omicron's immune evasion characteristics, guided by independent data. We set "# $ = 0.7 and "# ,|$ = 0.2, corresponding to a drop in protection against infection from 88% for pre-Omicron variants (Fig. 2J ) to 47% for Omicron (17, 23) , and a drop in protection against transmission from 60% (24) to 52%, reflecting weak immune evasion on onward transmission (18) . Under this scenario, the estimated ! "#$%&'( / ! )*+,was 2.4, the infection rate (24)). We assessed the risk of future recurrences of different SARS-CoV-2 variants after the initial Omicron wave had subsided, assuming possible changes in contacts to account for erosion in adherence to SARS-CoV-2 15 interventions over time (models detailed in Materials and Methods Section 6). Even at the contact rate estimated during the Delta wave, the level of population immunity would not be able to prevent a recuring Omicron epidemic unless past Omicron infection conferred high and durable protection ( Figure 3G ). If contact rates increased 100% relative to current levels, a return of the Omicron variant would likely cause outbreaks irrespective of the protection afforded 20 by prior Omicron infections (outbreak conditions defined as growth rate larger than zero, Figure 3H ). A 100% increase in contacts is plausible given estimated levels of transmission reduction in South Africa at the end of 2021, which reflect the combined effect of population behavior and seasonality (see Materials and Methods, Section 5.5 and Table S3 ). In contrast, if contact rates were to remain the same as those observed during the Delta wave, the Delta variant would be 25 unlikely to return and cause new outbreaks, across all ranges of Omicron-specific immunity assumptions against Delta ( Figure 3I ). With 100% higher contact rates, some scenarios favored a re-emergence of Delta if Omicron did not protect well against Delta ( Figure 3J ). We also explored scenarios involving a hypothetical new variant X with the same basic reproduction number and generation time as the Delta variant, and at equal antigenic distance from Omicron and pre-30 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 13, 2022. ; https://doi.org /10.1101 /10. /2022 Omicron variants. Accordingly, the relative risk of reinfection with variant X was assumed to be the same irrespective of whether an individual was primed with pre-Omicron or Omicron antigens. With an increased contact rate compared to Delta ( Figure 3J ), we found more opportunities for variant X to cause recuring epidemic waves in the explored ranges of parameters, primarily by escaping immunity conferred by pre-Omicron variants ( Figure 3K ). Emerging variants with such 5 antigenic features need to be closely monitored in the future. On the other hand, if heterologous prime and boost infections (accounting for 45.7% of the population, Figure 3F ) were found to elicit broadly protective antibodies and confer a high level of cross-protection against new variant X, only a small parameter space would be favorable to variant X epidemics ( Figure 3K ). Given that a large fraction of the world's population has been primed by vaccination or infection with pre- 10 Omicron antigens, it is important to understand how heterologous boosting by Omicron may broaden the immune repertoire, and how this could translate into clinical protection against antigenically novel variants. For a period of 13 months, the PHIRST-C study carefully monitored SARS-CoV-2 infections in 15 222 households at a rural and an urban site in South Africa. These data provide a unique opportunity to characterize variant-specific shedding kinetics, transmission dynamics within the household, and the degree of immune protection conferred by prior infection before the Omicron surge. Longitudinal rRT-PCR data available for each infection episode at roughly 3-day resolution allowed for reconstruction of the intensity of SARS-CoV-2 exposures exerted on each household 20 member based on Ct values. We found that individuals were more infectious in the RNA proliferation than clearance stage. Prior to the emergence of Omicron, substantial population immunity had accumulated through prior infection, with high and durable protection against symptomatic and asymptomatic reinfection, in line with prior findings (30, 31). These detailed cohort data allowed us to project the full scope of the Omicron epidemic and assess possible futures. Overall, even with a high degree of immunity post the Omicron wave (with over 90% of the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 13, 2022. ; https://doi.org /10.1101/2022.02.11.22270854 doi: medRxiv preprint population previously exposed to SARS-CoV-2 antigens), recurrence of past or antigenically novel variants is plausible, especially if post-Omicron behavioral changes increase contacts. The disease burden of future SARS-CoV-2 epidemic waves depends on the intrinsic severity of the variants themselves as well as the level of protection conferred by pre-existing immunity (32). Current evidence suggests that while Omicron is able to evade immunity against infection to a 5 significant degree, protection against severe outcomes remains high (17, 33, 34) . Our model's projections also suggest a low clinical burden of Omicron, with a greater than 10-fold reduction in infection case ratio relative to prior waves ( Figure 3E , Table S1 ). If existing immunity can sustain protection against severe outcomes over long timescales, the disease burden of future epidemic waves would be attenuated even if infections were widespread. However, if protection against 10 severe outcomes waned over time, vaccine boosting would likely be needed to compensate for loss of protection. As the PHIRST-C sampling scheme was not symptom-driven, it allowed us to capture shedding kinetics in both symptomatic and asymptomatic individuals. We observed that most infections 86.8% (581/669) were asymptomatic, but asymptomatically infected individuals transmitted the 15 virus within their households. For context, in the South African winter seasons of 2017-2018, approximately half of the influenza infections within the PHIRST-C cohorts were asymptomatic (35). The transmission potential of asymptomatic or pre-symptomatic SARS-CoV-2 infections identified in our study is in sharp contrast with SARS-CoV-1, where most transmission occurs after symptom onset (36). It is also worth noting in our cohort data, prior infections, whether 20 symptomatic or not, conferred durable protection against reinfection. We found that the shedding kinetics of SARS-CoV-2 were characterized by a rapid RNA proliferation stage until peak viral load, followed by a more gradual RNA clearance stage. The median duration of rRT-PCR positivity lasted 10.5 days (IQR 6.3 -14.0 days) with median peak Ct = 23.1 , in agreement with other high-frequency sampling studies (37, 38) . Reinfections had shorter 25 durations of rRT-PCR positivity and lower shedding peaks compared to primary infections ( Figure 2 H-I), which would be expected to decrease the probability of onward transmission. Our findings align with reports of reduction in viral shedding among vaccine breakthroughs relative to primary infections, prior to the occurrence of the Omicron variant (39-42). Interestingly, we observed variation in infectiousness through the course of infection, after adjusting for Ct values, whereby 30 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 13, 2022. an individual in the proliferation stage tends to be more infectious than one in the clearance stage. The post-peak decline in infectiousness coincides with the onset of adaptive immune responses that work to suppress the on-going infection (43). The observed decline in infectiousness in the RNA clearance stage also could be due to neutralization of some viral particles by antibodies, precluding productive transmission. 5 The peak of COVID-19 hospitalizations during the Omicron wave was lower than that during the Delta wave in South Africa (44), despite our model projecting a much higher infection rate for Omicron than Delta. This is compatible, however, with some lines of evidence suggesting a lower severity of the Omicron variant in naïve individuals, combined with robust infection and vaccineinduced immunity against severe Omicron disease (17, 45) . However, it is important to stress that, 10 in South Africa, immunity accumulated prior to the Omicron wave was mostly through prior infections, due to a delayed start and slow rollout of the vaccine campaign (46). As a result, the proportion of the population infected by pre-Omicron variants was substantially higher in South Africa than in countries that experienced faster vaccine rollout and/or effective mitigation strategies. 15 A few caveats are worth noting. First, our findings about the persistence of infection-induced immunity are based on a 13-month study. The duration and quality of protective immunity over longer timescales remain open questions. Recent studies have found that antibody responses improve over time through affinity maturation (47, 48) and that long-lived plasma cells can be identified in the bone marrow at least one year after infection, suggesting that immunity conferred 20 by infection or vaccination could be potent and durable against non-immune evasive variants (49). Persistent germinal center responses and durable T cell memory have also been observed among vaccine recipients (50-52). However, how the protection holds up against immune-evasive variant such as Omicron remains an outstanding question. Unfortunately, the PHIRST-C cohorts did not cover the Omicron wave, thus we could not directly measure immune protection at the individual 25 level and relied on modelling of population-level dynamics. Post-Omicron serologic surveys following up the cohort population could provide deeper insight into the full impact of the Omicron wave. In our projections of SARS-CoV-2 resurgences, we did not consider waning explicitly since our cohort data did not support pronounced waning of infection-induced immunity. Accordingly, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 13, 2022. ; https://doi.org /10.1101 /10. /2022 our projections are most relevant to short time scales, in the order of a few months. Interestingly, we find that resurgences are likely even over short time horizons. A second caveat relates to missed infection episodes, despite frequent rRT-PCR testing. In total, 21% (303407 person-days/1472400 person days) of the total person-days of observation were excluded from the regression during the entire study period due to missing nasal swab visits, 5 missing serologic status, or experiencing an active infection episode. For example, 14% (90/639) of individuals who seroconverted during the study lacked rRT-PCR confirmation of active infections (i.e., their first serologic test was negative, but they seroconverted later). This could possibly be due to 1) delayed seroconversion from infection episodes occurring prior to the first nasal specimen, 2) infection episodes that occurred during missed routine household visits, 3) a 10 shorter duration of rRT-PCR positivity than the interval between consecutive nasal swabbing (3 days), 4) false positives in serology test results or 5) false negatives of the rRT-PCR assay specimen (due to specimen quality issues or detection limit of the rRT-PCR). A third caveat relates to the simplicity of the contact structure in our transmission models. Projections of the trajectories of Delta, Omicron, and variant X did not address heterogeneity due 15 to age-specific susceptibility, transmissibility, and contact patterns. Nor did we consider individual variation in infection and vaccine-derived protection. Heterogeneity in mixing patterns and immune protection could lead to a lower infection rate when compared to homogeneous models with the same basic reproduction number (53, 54), thus the size of the Omicron epidemic could be inflated in our projections. In addition, our size projections could be inflated if the Omicron's serial 20 interval was shorter (corresponding to a lower basic reproduction number) than that the range of values explored. Population surveys on active infections during the Omicron wave as well as paired-sera surveys before and after the Omicron wave will be necessary to confirm the true scale of the Omicron epidemic. In conclusion, our study provides an in-depth analysis of the kinetics of viral shedding, 25 transmission dynamics, and persistence of immunity conferred by sequential exposures to different SARS-CoV-2 variants, and how these factors contribute to shaping the Omicron and post-Omicron phases. We found durable cross-protective immunity conferred by prior infection against pre-Omicron variants. However, Omicron successfully breached population immunity due to a . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 13, 2022. ; https://doi.org /10.1101 /10. /2022 combination immune escape and increased transmissibility, reinfecting a large fraction of the population and leaving a complex immune landscape in its aftermath. With increasing contacts as the Omicron wave subsides, several possible scenarios for SARS-CoV-2 recurrences are possible, involving both old and new variants. Further work on how immunity may strengthen and broaden upon sequential exposures with different variants and vaccination episodes will be important to J. du Toit, F. X. Gómez-Olivé, F. S. Dawood, T. Mkhencele, K. Sun, C. Viboud, S. Tempia, for the PHIRST group, SARS-CoV-2 incidence, transmission and reinfection in a rural and an urban setting: . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 13, 2022. ; https://doi.org /10.1101 /10. /2022 results of the PHIRST-C cohort study, South Africa, 2020-2021. bioRxiv ( CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 13, 2022. ; https://doi.org /10.1101 /10. /2022 CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 13, 2022. ; https://doi.org /10.1101 /10. /2022 Immunisations CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 13, 2022. ; https://doi.org /10.1101 /10. /2022 Omicron VOC transmission in Danish households. bioRxiv (2021) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 13, 2022. ; https://doi.org /10.1101 /10. /2022 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 13, 2022. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 13, 2022. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 13, 2022. ; https://doi.org /10.1101 /10. /2022 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 13, 2022. ; https://doi.org /10.1101 /10. /2022 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 13, 2022. ; https://doi.org /10.1101 /10. /2022 Pfizer first and second doses 11 (2) 28 (5) Table 1 : PHIRST-C study June 2020 -August 2021, characteristics of the population and SARS-CoV-2 infections at two study sites, South Africa. *PLWH: persons living with HIV . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 13, 2022. ; https://doi.org /10.1101 /10. /2022 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 13, 2022. ; https://doi.org /10.1101 /10. /2022 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 13, 2022. ; https://doi.org /10.1101 /10. /2022 Omicron: individuals who were infected by Delta first then infected by Omicron; Others-Omicron: individuals who were infected by a variant other than D614G, Beta, Delta and Omicron first then infected by Omicron; Repeat exposures: individuals who were exposed to SARS-CoV-2 antigens more than once (through vaccination or infection) without Omicron infection; Repeat exposures-Omicron: individuals who were exposed to SARS-CoV-2 antigens more than twice (through vaccination or infection) then infected by Omicron. 5 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 13, 2022. ; https://doi.org/10.1101/2022.02.11.22270854 doi: medRxiv preprint We conducted a prospective household cohort study of SARS-CoV-2 transmission at an urban and a rural site in South Africa from July 2020 to August 2021(4). The rural site was in Agincourt, a rural community in Mpumalanga Province, which has been a longstanding health and socio-demographic surveillance system site. The urban site was 5 in Klerksdorp, an urban community located in the North West Province. This study was built upon the larger multi- year Prospective Household cohort study of Influenza, Respiratory Syncytial virus and other respiratory pathogens community burden and Transmission dynamics (PHIRST), which was conducted from 2016 to 2018 to monitor transmission of respiratory pathogens (55). The study was repurposed for SARS-CoV-2 during the pandemic. To study infection and reinfection with SARS-CoV-2, a total of 222 households (114 in the rural site and 108 in the urban site) 10 with at least 3 household members were enrolled between July 2020 and August 2021, consisting of 638 and 557 participants in the rural and urban site, respectively. In the rural site, we first approached households from the 2017 and 2018 cohorts, and in the urban site, those from the 2016, 2017 and 2018 cohorts. To supplement the sample size of the cohorts, we enrolled additional households at each site using the same methods as for the initial PHIRST study. Baseline demographic factors and information on underlying medical conditions were collected at enrollment (Table 15 1). Throughout the study period, household members were visited twice a week by study nurses and trained lay fieldworkders for collection of biological and clinical data. At each visit, upper respiratory tract specimens were collected using mid-turbinate nasal swabs, irrespective of symptom presentation. Data on symptoms, healthcare seeking behavior, hospitalization and death were captured at each follow up visit on a REDCap tablet-based real-time database. Respiratory specimens were tested by rRT-PCR for SARS-CoV-2. The lineage types of positive rRT-PCR 20 specimens were determined by variant-specific rRT-PCR assay. Sera were collected at enrollment and approximately every 2 months during the 11-month follow-up period from all participants (see Figure 1 for timeline) and tested for the presence of SARS-CoV-2 antibodies. The detailed laboratory methods were previously described (55). To briefly summarize, nucleic acids for real-time reverse transcription polymerase chain reaction (rRT-PCR) tests were extracted using the Hamilton Microlab Serum specimens were collected using venous blood, centrifuged into serum separator tubes and stored refrigerated immediately and transported to NICD. Aliquots of prespecified volume according to manufacturer instructions . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 13, 2022. ; https://doi.org /10.1101 /10. /2022 were tested for the presence of SARS-CoV-2 antibodies by the Roche Elecsys Anti-SARS-CoV-2 assay against nucleocapsid (N) antigen (56). Assay readout above or equal to cutoff index 1 is considered as sero-positive, while below cutoff index 1 is considered as sero-negative. Negative control validations were performed using serum specimens from participants at both study sites prior to 2020 (4) . An independent study benchmarking performances of available commercial and laboratory serologic assays demonstrated that the Roche Elecsys Anti-SARS-CoV-2 5 assay had high sensitivity and specificity across a wide range of severity spectrum for at least 6 months post-infection (57). Combining the longitudinal rRT-PCR assays and serological test results from the two study sites, we found that the seroconversion rate was 97.6% (583/600) among primary infection episodes with at least one blood specimen collected 30 days after their first rRT-PCR positive test. Among 639 individuals with negative serological specimen(s) after their first blood specimen was taken but who seroconverted later, 86% (549/639) were confirmed by rRT-PCR during the study period, suggesting that twice-weekly rRT-PCR testing captured most of the infections during the study 15 period. Among 706 seroconverted individuals with at least one follow-up blood specimens after seroconversion, only 40 (5.7%) later sero-reverted (sero-reversion is defined as sero-converted individual who became sero-negative the subsequent serologic test). The baseline characteristics of all individuals are reported in Table 1 . 10% individuals received at least one dose of SARS-CoV-2 vaccine and 5% were fully vaccinated within the study period of PHIRST-C. We censored individuals after their vaccination episode. 20 For each individual in the study, we defined the duration of a SARS-CoV-2 infection episode as the time interval between the first and the last of a set of positive rRT-PCR test, where consecutive positive tests were separated by less than 30 days. If at least one positive rRT-PCR test within the infection episodes was identified as any of the 25 variants of concern (VOC) (defined by the WHO) Alpha (B. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 13, 2022. ; https://doi.org /10.1101 /10. /2022 When interpreting Ct values from rRT-PCR test by the Seegene Allplex™ 2019-nCoV kit, it is important to stress that the Ct value of a single rRT-PCR test is not a direct measurement of the quantity of viral genetic material present in an individual specimen (in absolute terms) (58). Many factors could influence the Ct value of a rRT-PCR test, including but not limited to the specimen quality, extraction method, chemistry of reagents, gene targets. Further, Ct values cannot be directly compared between assays of different types (59). However, comparing serial Ct values and/or 5 Ct values of different groups of population collectively, based on rRT-PCR tests from the same assay and laboratory setting, does reflect the relative variation in terms of viral genetic material concentration over time and between population subgroups (58, 59). We measure the viral RNA shedding intensity of a given specimen as the differences between the cycle threshold value of Seegene Allplex™ 2019-nCoV kit's detection limit ( +$#$, = 40) to the N gene target Ct value of the 10 specimen, i.e. 12*%$#*( 3 = +$#$, − 12*%$#*( 3 . For the Ct value, we are only considering the N gene target to avoid between-target variation. In this study, instead of directly interpreting the Ct value of a single rRT-PCR test, we fit a mathematical model to capture the temporal kinetics of dCt for longitudinally collected specimens and extract statistical summaries of RNA shedding intensity for each infection episode. In particular, following the method presented in (60), for each infection episode, we modelled the dCt kinetics during the "RNA proliferation stage", 15 characterized by linear growth in dCt until a peak in dCt is reached; and during the "RNA clearance stage", characterized by linear decline (in dCt) from the peak until the last rRT-PCR positive result. The duration of the "RNA proliferation stage" 2 was defined as the time from dCt first exceeding the detection threshold (i.e., 12*%$#*( 3 > 0, 12*%$#*( 3 < 40) until the peak of dCt; the duration of the "RNA clearance stage" % was defined as the time from peak dCt to Ct dropping below detection threshold (i.e., 12*%$#*( The fit of the RNA shedding trajectories for each variant are shown in Figure 2A -G. In addition, we performed 25 multivariable regression analysis to evaluate the dependencies of duration of rRT-PCR positivity and peak dCt on participants' characteristics including age, sex, BMI, HIV infection status, symptom status, variant type, and evidence of prior infection. Since the nasal swab sampling period ended on August 28, 2021, around the peak of the Delta wave in both sites, we limit our analysis to infection episodes with first positive PCR sample 30 days prior to the end of sampling to avoid censoring bias. The result of the regression is presented in Figure 2H -I. 30 For individuals who seroconverted without a rRT-PCR confirmed infection episode (prior to the start of the PHIRST-C cohort), we assigned the lineage type of the individual's unobserved infection according to lineages' prevalence (based on the infection episodes that had lineage information) at the study site in the month of the earliest seropositive 35 specimen. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 13, 2022. ; https://doi.org /10.1101 /10. /2022 For each individual in the urban and rural sites, we first reconstructed the status of prior and ongoing infections at a daily time resolution, based on the lineage-typed infection episodes and serologic results described in Section 3.3 and 3.4 above. Specifically, we denoted a person-day observation of individual 's infection status at day as $ , . We set , where is the sum over all infected household members at time . We further discriminated the "force of infection" during the RNA proliferation and RNA clearance phases of infections in 25 household members. We estimated the weekly SARS-CoV-2 community prevalence as the prevalence of each variant in the entire study site (no of variant-specific infections that week/population tested that week). Individual and household level random effects were also included in the logistic regression. Since the nasal swab sampling period ended on August 28, 2021, around the peak of the Delta wave in both sites, we limit our analysis to infection episodes with first positive PCR sample 30 days prior to the end of sampling to avoid 30 censoring bias. In total, 21% (303407 person-days/1472400 person days) of the total person-days of observation were excluded from the regression during the entire study period due to missing nasal swab visits, missing serologic status, or individuals experiencing an active infection episode. A household with an individual with chronical SARS-CoV-2 infection was also excluded. The results of the regression are presented in Figure 2J . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 13, 2022. ; https://doi.org /10.1101 /10. /2022 In this Section, we use PHIRST-C's urban site as a sentinel for SARS-CoV-2 antigen exposure(s) history (including both infection and vaccination) for the broader district where the study is located (Dr Kenneth Kaunda District). We reconstruct the population-level prevalence of different type of antigen exposures over time before Omicron and use this information as the initial condition in models that project the impact of Omicron. We focus on the urban site (Klerksdorp) as it is a major city of the Dr Kenneth Kaunda District. Table S1 . Based on the variant-specific reporting rate E ( ∈ { 614 In addition to allowing to trace SARS-CoV-2 infection history in detail, the PHIRST-C cohort also recorded Where ∈ { 614 , , , , }. In Figure S1 (below) and Figure 3F bottom panel, we visualize the proportion of population with a specific SARS-CoV-2 antigen exposure history. Omicron wave 30 To project the impact of Omicron, we need to model how immunity from infection with pre-Omicron variants and/or vaccination will impact the probabilities of infection, transmission and severe outcomes. The effectiveness of protective immunity ( ) can be measured very broadly as = 1 − where is the relative risk of an outcome of interest (infection, transmission, hospitalization, etc.) and the comparison is against individuals with no prior 35 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 13, 2022. ; https://doi.org /10.1101 /10. /2022 immunity or with different types of immunity. In particular, we consider three aspects of protection from prior infection/vaccination: 1) Prior infection/vaccination could reduce the host's susceptibility to reinfection $ , measured as $ = 1 − $ where $ is the relative risk of reinfection/breakthrough infection when compared to the infection risk in a naïve population, controlling for same level of exposure. 5 2) Prior infection/vaccination could reduce the risk of onward transmission given reinfection/breakthrough infection ,|$ , measured as ,|$ = 1 − ,|$ where ,|$ is the relative risk of onward transmission for reinfections/breakthrough infection when compared to that of primary infections, conditional on the same contact rate. Here ,|$ = ,M|$ × ,1|$ can be further broken down into the product of reduction in the duration and intensity of shedding ( ,M|$ and ,1|$ ). 10 3) Prior infection/vaccination could reduce the risk of disease given reinfection/breakthrough infection. The concept of COVID-19 disease is generic and could encompass a wide spectrum of severity endpoint including symptomatic cases, hospitalizations, and deaths. In this study, we used symptomatic illness as the severity end point. The effectiveness of protective immunity against being symptomatic case, conditional on infection can be measured as %|$ = 1 − %|$ , where %|$ is the relative risk of disease for 15 reinfections/breakthrough infections compared to primary infections. Repeat exposures to SARS-CoV-2 antigens can result from repeated infections, booster shots following primary vaccine schedule(s), infection following vaccination or vice versa. Multiple exposures could stimulate a recall 20 response and boost the level of protective immune effectiveness through reducing further from the baseline protective immunity provided by primary exposure. For example, let's denote the protective immunity conferred by primary infection with a pre-Omicron (pOm) strain as 2"# ( ) = 1 − 2"# ( ). We can express the level of protective immunity conferred by reinfection with pre-Omicron strains as 2"#/2"# ( ) = 1 − 2"#/2"# ( ) = 1 −`2 "# ( )a 0 measuring the degree of immunity boosted by 25 reinfection with a pre-Omicron strain. For 2"# ( ) < 1 ), the larger 2"# , the greater the reduction 2"#/2"# ( ) when compared to 2"# ( ), and the higher the protection conferred by boosting. On the other hand, in face of an antigenically distinct variant like Omicron, prior immunity may not be as efficacious due to reduced ability to recognize the antigen through immune memory, leading to elevation in and consequently reduction in . For example if we denote the protective immunity conferred by primary infection with a pre-Omicron 30 strain against refection by pre-Omicron as 2"# ( ) = 1 − 2"# ( ), we can express the level of protective immunity conferred by pre-Omicron strain infection against Omicron (Om) as 2"# ( ) = 1 − 2"# ( ) = 1 −`2 "# ( )a